A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis
NCT02398994 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2
Last updated 2016-07-20
Summary
This multi-center randomized controlled trial evaluates if the addition of intravenous immunoglobulin to standard treatment of corticosteroids improves outcome in children and adults with first episode of Transverse Myelitis of Neuro-myelitis optica. Half of participants will receive corticosteroids alone, whilst the other half will receive corticosteroids plus intravenous immunoglobulin.
Conditions
- Myelitis, Transverse
- Neuromyelitis Optica
Interventions
- DRUG
-
Intravenous Methylprednisolone
Sponsors & Collaborators
- collaborator OTHER
-
Barts and the London School of Medicine and Dentistry
collaborator OTHER -
Cardiff University
collaborator OTHER -
University College, London
collaborator OTHER -
King's College Hospital NHS Trust
collaborator OTHER -
Great Ormond Street Hospital for Children NHS Foundation Trust
collaborator OTHER -
Barts & The London NHS Trust
collaborator OTHER -
Alder Hey Children's NHS Foundation Trust
collaborator OTHER -
Walton Centre NHS Foundation Trust
collaborator OTHER -
Oxford University Hospitals NHS Trust
collaborator OTHER -
Birmingham Women's and Children's NHS Foundation Trust
collaborator OTHER -
University Hospital Birmingham NHS Foundation Trust
collaborator OTHER -
Cardiff and Vale University Health Board
collaborator OTHER_GOV -
North Bristol NHS Trust
collaborator OTHER -
University Hospitals Bristol and Weston NHS Foundation Trust
collaborator OTHER -
Manchester University NHS Foundation Trust
collaborator OTHER_GOV -
Northern Care Alliance NHS Foundation Trust
collaborator OTHER -
University Hospital Southampton NHS Foundation Trust
collaborator OTHER -
Newcastle-upon-Tyne Hospitals NHS Trust
collaborator OTHER -
Nottingham University Hospitals NHS Trust
collaborator OTHER -
NHS Lothian
collaborator OTHER_GOV -
Guy's and St Thomas' NHS Foundation Trust
lead OTHER
Principal Investigators
-
Ming Lim, MB, PhD · Guy's and St Thomas' NHS Foundation Trust
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 1 Year
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-03-31
- Primary Completion
- 2016-03-31
- Completion
- 2016-03-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Mycophenolate Mofetil in Myasthenia Gravis
NCT00285350 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment With TNF Blockade, Infliximab, in Patients With Myositis
NCT00443222 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy
NCT06462144 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders
NCT04064944 ·Status: UNKNOWN ·Phase: PHASE2
-
Add-on Intravenous Immunoglobulins in Early Myositis
NCT05832034 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Intravenous Immunoglobulin Therapy in Optic Neuritis
NCT00000117 ·Status: COMPLETED ·Phase: PHASE3
-
Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial
NCT05545384 ·Status: RECRUITING ·Phase: PHASE3
-
In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
NCT05544448 ·Status: COMPLETED ·Phase: NA
-
Low-dose Interleukin-2 in Combination With Standard Therapy on Idiopathic Inflammatory Myopathy
NCT04237987 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy
NCT00004286 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
NCT04540497 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT00001287 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study of Intravenous Immunoglobulin
NCT00468273 ·Status: COMPLETED ·Phase: PHASE3
-
The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy
NCT06599697 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
NCT07039916 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004 ·Status: RECRUITING ·Phase: PHASE3
-
IA or PE - What is the Best Treatment Option of Steroid Refractory Neurological Autoimmune Diseases
NCT04687332 ·Status: COMPLETED ·Phase: NA
-
Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
NCT01828294 ·Status: TERMINATED ·Phase: PHASE1
-
A Prospective Cohort Study of Myasthenia Gravis in China
NCT06006832 ·Status: RECRUITING
-
Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy
NCT02971683 ·Status: COMPLETED ·Phase: PHASE3
-
Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone
NCT00004645 ·Status: UNKNOWN ·Phase: PHASE3
-
Phase 3 IGIV, 10% in Alzheimer´s Disease
NCT01524887 ·Status: TERMINATED ·Phase: PHASE3
-
Disease-Modifying Treatments for Myasthenia Gravis
NCT03490539 ·Status: COMPLETED
-
Interest of Mycophenolate for CIDP Weaning
NCT02494505 ·Status: COMPLETED ·Phase: PHASE3
-
CPI Combination Therapy for Autoimmune Encephalitis
NCT03542279 ·Status: COMPLETED ·Phase: NA